The Global point of care diagnostic market was valued at $23.7 billion in 2022 and is projected to reach $46.7 billion by 2030, growing at a CAGR of 14.5% during the forecast period.

The global point of care diagnostic market refers to the market for medical diagnostic tests that can be performed near the patient, rather than in a centralized laboratory. These tests are typically conducted in a doctor's office, hospital room, or at home, and provide fast and accurate results to aid in diagnosis and treatment decisions.

The market for point of care diagnostics has been growing rapidly in recent years, driven by factors such as the increasing prevalence of chronic diseases, the need for rapid and accurate diagnostic testing in emergency situations, and the development of portable, easy-to-use diagnostic devices.

The market is segmented by product (glucose monitoring, infectious disease testing, cardiac markers, hematology testing, coagulation testing, pregnancy and fertility testing, urinalysis testing, others), mode of delivery (OTC, prescription-based), end-user (professional diagnostic centers, home care settings, research laboratories, others), and geography.

North America is currently the largest market for point of care diagnostics, followed by Europe and the Asia Pacific. Key players in the market include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Danaher Corporation, Becton, Dickinson and Company, and Bio-Rad Laboratories.

Market Dynamics

Driving Factors

There are several driving factors contributing to the growth of the global point of care diagnostic market:

Advancements in technology: Technological advancements have made it possible to develop portable and easy-to-use diagnostic devices that can be used in a variety of settings. These devices are becoming more affordable and accessible, driving adoption and market growth.

Increasing demand for home-based testing: The COVID-19 pandemic has accelerated the demand for home-based testing, as people look to avoid crowded healthcare facilities. Point of care diagnostics that can be used at home have become more popular, providing convenience and reducing the burden on healthcare systems.

Restraining Factors

The global point of care diagnostic market is growing rapidly, there are also several restraining factors that could impact its growth:

High cost of some point of care diagnostic tests: While some point of care diagnostic tests are affordable and accessible, others may be more expensive than centralized laboratory tests. This could limit their adoption, particularly in lower-income countries or regions with limited healthcare resources.

Limited reimbursement policies: Reimbursement policies for point of care diagnostic tests can vary widely between countries and regions, which could impact their adoption and market growth.

Challenges Factors

The global point of care diagnostic market faces several challenges that could impact its growth and adoption:

Limited infrastructure: Point of care diagnostic tests require appropriate infrastructure, including laboratory equipment, reagents, and trained personnel, which may be limited or unavailable in some settings. Improving infrastructure and access to resources is necessary to expand the use of point of care diagnostics.

Data management and privacy: Point of care diagnostic tests generate large amounts of data that need to be properly managed and secured to ensure patient privacy and confidentiality. Developing appropriate data management protocols and ensuring compliance with data protection regulations is necessary to expand the use of point of care diagnostics.

Opportunity Factors

The global point of care diagnostic market presents several opportunities for growth and expansion:

Integration with digital health technologies: Integration with digital health technologies such as telemedicine and remote monitoring can improve the efficiency and accessibility of point of care diagnostics. Developing digital health solutions that incorporate point of care diagnostic tests presents opportunities for market growth and expansion.

Collaboration and partnerships: Collaboration and partnerships between manufacturers, healthcare providers, and regulatory bodies can help to address challenges and accelerate the adoption of point of care diagnostics. Developing strategic partnerships presents opportunities for growth and expansion into new markets and applications.

Segmentation Analysis

Product Type Outlook

Glucose monitoring kits are one of the largest product segments in the point of care diagnostic market. These kits are used for the management of diabetes and include blood glucose meters and test strips. Infectious disease testing kits are used for the rapid diagnosis of infectious diseases, such as influenza, HIV, and hepatitis. These tests can be performed in a variety of settings, including hospitals, clinics, and community health centers.

Cardiovascular testing kits are used for the diagnosis and management of cardiovascular diseases, such as heart disease and hypertension. These tests include blood pressure monitors, cholesterol test kits, and coagulation tests. Pregnancy and fertility testing kits are used for the rapid and convenient detection of pregnancy and fertility status. These tests include pregnancy test kits, ovulation test kits, and male fertility test kits.

End Use Outlook

Hospitals are one of the largest end-users of point of care diagnostic tests, driven by the increasing demand for rapid and accurate diagnosis in emergency and critical care settings. Clinics, including community health centers, urgent care centers, and physician offices, are another significant end-user of point of care diagnostic tests. These settings often have limited laboratory infrastructure and rely on point of care diagnostic tests for rapid diagnosis and treatment.

Home care settings are emerging as a significant end-user of point of care diagnostic tests, driven by the increasing demand for self-monitoring and management of chronic diseases, such as diabetes and hypertension. Other end-users of point of care diagnostic tests include research laboratories, academic institutions, and diagnostic testing centers.

Each of these end-user segments presents unique growth opportunities and challenges, depending on factors such as market demand, regulatory environment, and technological advancements. As the point of care diagnostic market continues to grow and evolve, we can expect to see continued innovation and expansion in each of these end-user segments. Additionally, as the healthcare landscape continues to shift towards more patient-centered care, we can expect to see increasing demand for point of care diagnostic tests in home care settings.

Regional Analysis

North America is the largest market for point of care diagnostic tests, driven by the presence of advanced healthcare infrastructure, increasing prevalence of chronic diseases, and favorable regulatory environment.

Europe is another significant market for point of care diagnostic tests, driven by the increasing demand for rapid diagnosis and treatment, aging population, and the presence of established healthcare infrastructure.

Asia Pacific is emerging as a significant market for point of care diagnostic tests, driven by the increasing prevalence of chronic diseases, improving healthcare infrastructure, and rising healthcare expenditure.

Latin America is another growing market for point of care diagnostic tests, driven by the increasing demand for rapid diagnosis and treatment, improving healthcare infrastructure, and rising healthcare expenditure.

The Middle East and Africa is a relatively small market for point of care diagnostic tests, but is expected to experience significant growth in the coming years, driven by the increasing demand for rapid diagnosis and treatment, rising healthcare expenditure, and improving healthcare infrastructure.

Scope Of Report:

The Global Point of Care Diagnostic Market has been segmented into:

By Product

• Glucose Testing
• Hb1Ac Testing
• Coagulation Testing
• Fertility/Pregnancy
• Infectious Disease
• HIV POC
• Clostridium Difficile POC
• HBV POC
• Pneumonia or Streptococcus Associated Infections

Respiratory Syncytial Virus (RSV) POC

• HPV POC
• Influenza/Flu POC
• HCV POC
• MRSA POC
• TB and Drug-resistant TB POC
• HSV POC
• COVID-19
• Other Infectious Diseases

Cardiac Markers

• Thyroid Stimulating Hormone
• Hematology
• Primary Care Systems

Decentralized Clinical Chemistry

• Feces
• Lipid Testing
• Cancer Marker
• Blood Gas/Electrolytes
• Ambulatory Chemistry
• Drug of Abuse (DOA) Testing
• Urinalysis/Nephrology

By End-use

• Clinics
• Pharmacy & Retail Clinics
• Physician Office
• Urgent Care Clinics
• Non-practice Clinics
• Hospitals
• Home
• Assisted Living Healthcare Facilities
• Laboratory

By Region

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Nordic Countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Market Players 

The global point of care diagnostics market is highly competitive and fragmented, with numerous players vying for market share. Some of the key companies in the market are:

• F. Hoffmann-La Roche Ltd.
• Danaher
• BD
• Qiagen
• Abbott
• Siemens Healthcare AG
• bioMerieux SA
• Zoetis, Inc.
• Instrumentation Laboratory
• Nova Biomedical
• Quidel Corp.
• Trividia Health, Inc.
• Sekisui Diagnostics
• Nipro Corp.
• Trinity Biotech
• Orasure Technologies, Inc.
• Spectral Medical, Inc. 

Abbott Laboratories is a leading player in the point of care diagnostic market, with a broad portfolio of diagnostic tests and systems. Roche Diagnostics is another significant player in the point of care diagnostic market, offering a range of diagnostic tests and systems for the rapid and accurate diagnosis of diseases.

Other notable players in the market include Quidel Corporation, bioMerieux SA, F. Hoffmann-La Roche Ltd., and Trinity Biotech, among others.

These players compete on the basis of product offerings, pricing, quality, and brand reputation, among other factors. As the point of care diagnostic market continues to grow and evolve, we can expect to see continued competition and innovation in the market, with players vying for market share and expanding their product offerings to meet evolving market demands.

Strategic Developments

In June 2021, Roche Diagnostics announced the acquisition of long-term partner TIB Molbiol, a leading supplier of high-quality PCR and real-time PCR-based research products and assays.

In May 2021, Abbott Laboratories announced the acquisition of Walk Vascular, a privately held medical device company focused on developing minimally invasive solutions for peripheral artery disease.

In April 2021, Becton, Dickinson and Company announced the acquisition of the medical device company Tepha, Inc., which specializes in the development of resorbable polymer technology for surgical applications.

In February 2021, Siemens Healthineers completed the acquisition of Varian Medical Systems, a leading provider of cancer care solutions and services.

In January 2021, Quidel Corporation announced the acquisition of Ellume, a digital diagnostics company focused on developing home-based diagnostic tests for infectious diseases.

In October 2020, Danaher Corporation announced the acquisition of the biopharmaceutical company Cytiva, which specializes in the development of advanced technologies and systems for bioprocessing and cell therapy.